Bart L. Scott, MD

Clinical Director, MDS/MPN and Myeloid Malignancies
Fred Hutch
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutch
Specialty:
Medical Oncology
“I know your disease and the latest treatments, but only you can guide me to meet your health needs.”
— Dr. Scott
What is your personal experience with cancer?

Cancer survivor, family member of a patient, physician — I’ve been all three. When I was in high school, my mom was diagnosed with breast cancer. After watching her go through what she did and seeing the doctors work with her, I knew that I wanted to be a doctor, too. Then, in my second year of medical school, I was diagnosed with Hodgkin lymphoma. That’s when I learned firsthand about the benefits of people participating in clinical trials. Thanks to those patients, I survived a disease that once had a high mortality rate. These experiences have made me more aware of what patients and families go through when cancer barges into their lives.

Lymphoma Cancer that begins in the cells of the immune system. There are two basic categories of lymphomas: Hodgkin lymphoma and non-Hodgkin lymphomas. Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
What do you want patients to know about clinical trials?

There’s often a misconception that participating in a clinical trial means you won’t get the best treatment. Actually, the opposite is true. Those who decide to join a trial tend to get far superior treatment compared to those who don’t. One reason is the level of monitoring: A team of experts in your particular disease will oversee your care very closely. Another reason is that you have access to the very latest therapies available, which may be more effective than conventional methods. There are no placebos. In the end, you have to decide what’s right for you, and clinical trials aren’t without risk. But choosing to participate in one means that you have the chance to help future patients while also helping yourself.

Clinical trial A type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis or treatment of a disease.

Provider background

Specialty: Medical Oncology

Area of clinical practice

Adult Blood and Marrow Transplantation, Hematologic Malignancies

Myelodysplastic syndromes (MDS)

I am the director of hematology and hematologic malignancies at SCCA as well as a medical oncologist who specializes in treating myelodysplastic syndromes (MDS). Sometimes referred to as “preleukemia,” MDS refers to a group of disorders in which the bone marrow fails to produce enough healthy blood cells. Treatment of this disease is improving rapidly because of clinical trials. I’m currently developing three treatment protocols for MDS, which affects between 13,000 and 20,000 patients in the U.S. every year. In addition to conducting research, I’m also focused on day-to-day patient interactions. In 2016, I received the Ali Al-Johani Award, which recognizes excellence in clinical patient care.

Myeloproliferative neoplasms (MPN)

One of my subspecialties is treating myeloproliferative neoplasms (MPN), a rare group of blood cancers caused by an overproduction of white or red blood cells or platelets. I coordinate the care of patients with MPN from all over the world, and I also conduct clinical trials of new drug therapies, such as pacritinib, for these cancers. In recent years, we’ve made a lot of progress in understanding the basic biology of MPN — in particular, some of the mutations that drive it — which makes it possible to develop more targeted therapies with fewer side effects.

Bone marrow The soft, spongy material in the center of your bones that produces all your blood cells, such as white blood cells, red blood cells and platelets. Medical oncologist A physician who has special training in diagnosing and treating cancer in adults using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A physician who has special training in diagnosing and treating cancer in adults using chemotherapy, hormonal therapy, biological therapy and targeted therapy. A medical oncologist is often the main health care provider for someone who has cancer. A medical oncologist also gives supportive care and may coordinate treatment given by other specialists. Platelet A tiny, disc-shaped piece of a cell that is found in the blood and spleen. Platelets help form blood clots to slow or stop bleeding and to help wounds heal. A tiny, disc-shaped piece of a cell that is found in the blood and spleen. Platelets are pieces of very large cells in the bone marrow called megakaryocytes. They help form blood clots to slow or stop bleeding and to help wounds heal. Having too many or too few platelets, or having platelets that do not work as they should, can cause problems. Checking the number of platelets in the blood may help diagnose certain diseases or conditions. Red blood cell A type of blood cell that carries oxygen in the body. Side effects A problem that occurs when treatment affects healthy tissues or organs. Some side effects of cancer treatment are nausea, vomiting, fatigue, pain, decreased blood cell counts, hair loss and mouth sores. Targeted therapy A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells while causing less harm to normal cells. A type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells while causing less harm to normal cells. Some targeted therapies block the action of certain enzymes, proteins or other molecules involved in the growth and spread of cancer cells. Other types of targeted therapies help the immune system kill cancer cells, or they deliver toxic substances directly to cancer cells and kill them. Targeted therapy may have fewer side effects than other types of cancer treatment. Most targeted therapies are either small molecule drugs or monoclonal antibodies.

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Alabama, Birmingham
Medical Degree
University of South Alabama-Mobile, School of Medicine
Residency
Johns Hopkins University, School of Medicine
Fellowship
University of Washington, Hematology-Oncology
Board Certification
Medical Oncology, 2003, 2019, American Board of Internal Medicine
Languages
English

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by Fred Hutch doctors. Many of these trials at Fred Hutch have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04161885
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)
Complete title
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Study ID:
NCT04485260
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Complete title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Publications

Many of our Fred Hutch doctors conduct ongoing research to improve standards of patient care. Their work is evaluated by other doctors and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this Fred Hutch provider has written.

Your care team

At Fred Hutch, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a patient care coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your doctor and assists with care procedures and treatments.
Patient care coordinator
Patient care coordinator
Your patient care coordinator works closely with you and your doctor and serves as your scheduler.

Insurance

Fred Hutch accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers